source
- Degron, CREATE, TenNor raise capital; Cabaletta posts CAR-T data💸 A Series A extension: US-China biotech Degron Therapeutics has collected an additional $40 million for its molecular glue degrader platform. The San Diego and Shanghai biotech has raised $95 mil…Endpoints · 3mo ago↗ source
- AstraZeneca follows Merck with Phase 3 win in bladder cancerA combination of AstraZeneca's Imfinzi with Pfizer and Astellas’ Padcev kept more bladder cancer patients alive than standard of care, the company said Thursday. AstraZeneca said it would seek appr…Endpoints · 3mo ago↗ source
- STAT+: BeOne wins FDA approval in lymphoma raceDiamantas takes the reins, Regenxbio stakes claim in Duchenne gene therapy, and more biotech news from The ReadoutSTAT · 3mo ago